https://www.sciencedirect.com/science/article/pii/S0944711321000738

标题应做：无明显肝毒性

View PDF
Download full issue
Phytomedicine
Volume 85, May 2021, 153531
Original Article
Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study
Author links open overlay panelLihua Zhang a †, Xin Zheng a †, Xueke Bai a, Qing Wang a, Bowang Chen a, Haibo Wang b, Jiapeng Lu a, Shuang Hu a, Xiaoyan Zhang a, Haibo Zhang a, Jiamin Liu a, Ying Shi c, Zhiye Zhou c, Lanxia Gan c, Xi Li a d, Jing Li a d e
Show more
Outline
Share
Cite
网页链接 Get rights and content
Under a Creative Commons license
open access
Abstract
Background
Qingfei Paidu Tang (QPT), a formula of traditional Chinese medicine, which was suggested to be able to ease symptoms in patients with Coronavirus Disease 2019 (COVID-19), has been recommended by clinical guidelines and widely used to treat COVID-19 in China. However, whether it decreases mortality remains unknown.
Purpose
We aimed to explore the association between QPT use and in-hospital mortality among patients hospitalized for COVID-19.
Study design
A retrospective study based on a real-world database was conducted.
Methods
We identified patients consecutively hospitalized with COVID-19 in 15 hospitals from a national retrospective registry in China, from January through May 2020. Data on patients’ characteristics, treatments, and outcomes were extracted from the electronic medical records. The association of QPT use with COVID-19 related mortality was evaluated using Cox proportional hazards models based on propensity score analysis.
Results
Of the 8939 patients included, 28.7% received QPT. The COVID-19 related mortality was 1.2% (95% confidence interval [CI] 0.8% to 1.7%) among the patients receiving QPT and 4.8% (95% CI 4.3% to 5.3%) among those not receiving QPT. After adjustment for patient characteristics and concomitant treatments, QPT use was associated with a relative reduction of 50% in-hospital COVID-19 related m

Results
Of the 8939 patients included, 28.7% received QPT. The COVID-19 related mortality was 1.2% (95% confidence interval [CI] 0.8% to 1.7%) among the patients receiving QPT and 4.8% (95% CI 4.3% to 5.3%) among those not receiving QPT. After adjustment for patient characteristics and concomitant treatments, QPT use was associated with a relative reduction of 50% in-hospital COVID-19 related mortality (hazard ratio, 0.50; 95% CI, 0.37 to 0.66 p < 0.001). This association was consistent across subgroups by sex and age. Meanwhile, the incidences of acute liver injury (8.9% [95% CI, 7.8% to 10.1%] vs. 9.9% [95% CI, 9.2% to 10.7%]; odds ratio, 0.96 [95% CI, 0.81% to 1.14%], p=0.658) and acute kidney injury (1.6% [95% CI, 1.2% to 2.2%] vs. 3.0% [95% CI, 2.6% to 3.5%]; odds ratio, 0.85 [95% CI, 0.62 to 1.17], p=0.318) were comparable between patients receiving QPT and those not receiving QPT. The major study limitations included that the study was an observational study based on real-world data rather than a randomized control trial, and the quality of data could be affected by the accuracy and completeness of medical records.
Conclusions
QPT was associated with a substantially lower risk of in-hospital mortality, without extra risk of acute liver injury or acute kidney injury among patients hospitalized with COVID-19.

大家觉得这个能不能证明其疗效呢

那么为什么这个效果并没有在使用中实际体现在数据上呢？

不能，因为两组人员并不是随机分组。

欢迎进一步的探讨

无肝毒性。仅这一标题。呵呵。

比较可惜的是，像这种过往数据统计的研究，因为现实中具体采用什么治疗策略影响因素非常多，不会考虑有人需要研究什么，🦠也在更新换代，因此要保证一套成系列的，前后应证可比的数据我觉得是比较悲观的。而相关单位大概也没有这个财力、动机和条件来亲自组织实验。毕竟无利不起早。总之，比较可惜。@贴吧用户_QeVWURy

抽烟有利于健康的论文也不少，都是烟草公司雇佣人研究的；
要多数学者都认可，充分的研究，才有一定的说服力，少数论文说明不了什么

好牛叉的杂志，上次说连花清瘟治新冠的文章就是它发的